Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-3186 in advanced solid tumors
NCT06787950Phase 2Not yet recruiting
- Sponsor
- Asieris Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ASN-3186 in solid tumor (advanced stage), sponsored by Asieris Pharmaceuticals. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ASN-3186
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06787950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787950.